Many adults discover that stubborn weight and persistent cravings resist even the most disciplined efforts
Oral semaglutide is made up of the same active ingredient as injectable GLP-1s, working to slow digestion, reduce appetite, regulate insulin sensitivity, and support weight loss
Even if the Wegovy negotiation continues, its quite possible it may not cover its use for weight loss unless patients can show they have cardiovascular comorbidities
This condition is associated with increased morbidity and mortality, multiorgan dysfunction, and a substantial economic burden on Healthcare systems
Tirzepatide is a newer medication that acts on both GLP-1 and GIP receptors, influencing both appetite and metabolism
When utilized as part of a medical weight management plan, GLP-1 medications can help reduce hunger, increase feelings of fullness, and encourage healthier food choices